A fraction (26%) of primary high grade (G4/5) prostate cancer presented with significant loss of PLZF expression also seemed to fit in the real clinical scenario, in which only a portion of high Gleason PCa progress and develop metastasis along their courses. This evidence concerns the gene ZBTB16 and prostate cancer.